Author
Neglected tropical diseases were at the forefront of a recent convening on human health and climate change.
Amid ongoing patent disputes over the mRNA platform, a significant scientific question remains unanswered: whether mRNA itself even is patent eligible.
Initiatives like CalRx may have far-reaching consequences for public health and access to medicines.
Recent articles emphasize the need to reform intellectual property protections for government-funded inventions of public health significance.
The regulatory landscape of health-related products contains loopholes that allow false or misleading claims to proliferate.
In January, the FTC released a draft rule that would ban non-compete clauses. This may promote competition and innovation in biotechnology.
An explanation of the key patents at stake in the intellectual property dispute between Moderna and Pfizer/BioNTech over COVID-19 vaccines.
The future of public health in an “RNA world” is on trial in a trade secrecy dispute worth $950 million.
The Truth Pill is a monumental work that convincingly shows that drug regulation is but a myth in India.
COVID-19 vaccine manufacturers refusing to share samples may be the latest example of the tragedy of the “anticommons” in biomedical research.
